Medical Device News Magazine

11/26/24: Philips and AWS Expand Strategic Collaboration to Advance HealthSuite Cloud Services and Power Generative AI Workflows “The collaboration between Philips and AWS gives healthcare providers scalable, secure-by-design cloud-enabled solutions to accelerate healthcare innovation,” said Matt Garman, CEO of AWS. “Combining Philips’ healthcare informatics portfolio with AWS generative AI capabilities gives clinicians access to imaging insights so they can deliver more effective and efficient care to patients anywhere, anytime, with best-in-class security and privacy.” More at https://lnkd.in/eJMaM4Xh

11/26/24: Poseida Therapeutics, Inc. Therapeutics Announces Agreement to be Acquired by Roche Holdings, Inc. - The proposed acquisition will establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies. It will include CAR-T programs for solid tumors and autoimmune diseases, along with Poseida's genetic engineering platform and related preclinical medicines. More on this news at https://lnkd.in/ervywN6j

11/26/24: Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the “AD-DMT Registry” in Japan Eisai and Biogen Japan will continue to contribute to the advancement of Alzheimer’s disease treatment through ongoing collaboration with academia. More at https://lnkd.in/eyC_8x5J

11/26/24: Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer - Hugh Salter, Chief Scientific Officer at Anocca, elaborated, "KRAS is an immensely important target in many cancer types, but has to date been challenging to address. KRAS mutations are a hallmark of PDAC, which is among the most difficult to treat cancers, and we believe TCR-T cell therapies and, in particular, our VIDAR-1 assets can be effective in addressing this target and providing a new solution in an indication with high unmet medical need.” Details at https://lnkd.in/et7wsAWb

11/21/24: The Role of Endovascular Specialists in the Multidisciplinary Approach to Postpartum Hemorrhage | Article By Dr. Adam Power, Co-Founder and CMO, Front Line Medical Technologies - He writes, "Postpartum hemorrhage (PPH) continues to challenge obstetric care despite ongoing medical advancements. With blood loss exceeding 500 ml in 6.3% to 13% of births and over 1000 ml in 1.9% to 2.8% of cases, PPH remains a significant concern. These figures are particularly worrying given that 500 ml is the established threshold for PPH following vaginal delivery. Cesarean sections often involve even more significant blood loss, frequently exceeding 1000 ml." Read more on what Dr. Power has to say. #FrontLineMedicalTechnologies https://lnkd.in/e2Q5ptdH

11/19/24: The Future of Precision Medicine Delivering ROI for the Healthcare Industry | By: @Gary Turner, Managing Director, Additive Manufacturing, Ricoh USA, Inc. Turner asks: What do orthopedic surgery and additive manufacturing have in common? 3D surgical guides. This experts shares his views. Read what he has to say at https://lnkd.in/eWRQHVNg

Can't wait to see everyone next week! #VEITH2024 #AortaED #AAA #Vascular #Endovascular #AIImaging

11/14/24 - Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market - Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets. https://lnkd.in/eJWgVQ-e

11/6/24: Transforming Diabetes Care: Why CGM Hardware Must Evolve for the Type 2 Population | By Dr. Chris Dawson, Head of Head of Biosensing at TTP plc. He writes, "The landscape of diabetes management is transforming, as continuous glucose monitoring (CGM) devices expand beyond Type 1 diabetes and into a rapidly growing Type 2 market. Changes to regulatory approvals and insurance coverage driven by improved patient outcomes have opened the door for non-insulin-dependent Type 2 patients to access CGM. Device manufacturers now face a new frontier: designing CGM hardware that meets the unique needs of an increasingly diverse patient population. For CGMs to realize their full potential in Type 2 diabetes management, it’s critical to rethink hardware design to cater to this population’s distinct requirements, improving usability, flexibility, and the quality of care." Read what he has to say at https://lnkd.in/e9GECmu9

11/4/24: Jason Whiting Appointed CEO of Avation Medical - details at https://lnkd.in/eCi_ZkmC